Autism Spectrum Disorder Treatment Market Size (2023 - 2030)

The market size of global autism spectrum disorder treatment was worth USD 4,700.1 million by 2030 with a CAGR of 3.8% during 2023 - 2030.

Autism spectrum disorder is a disability or neuro-development disorder. Generally, the disorders occur during the early stages of childhood and the disorder lasts lifelong. 

The recent outbreak of novel coronavirus (COVID-19) has severely affected many industries like chemical, agriculture, healthcare, etc. The World Health Organization (WHO) declared an emergency public health issue. The pandemic has affected the autism spectrum disorder treatment negatively. Throughout the pandemic period, children with autism need more help due to their difficulties in stereotyped behaviors, social communication. Because of the COVID-19, children with autism are unable to meet their rehabilitation centers. 

Market Drivers & Restraints

DRIVERS

The factors like the growing occurrence of autism in patients along with increasing awareness in people with developed possibilities of examining children boost the market growth globally. The augmenting research and development activities for providing efficient therapies, surging investments, and funds from the government, and growing organizing programs creating awareness in people are driving the ASD market growth. The advancements in technology in improving the healthcare of the patient along with modernization in the medical sector stimulate the market growth during the forecast period. 

RESTRAINTS

Shortage of professionals

Factors that limit the autism spectrum treatment market growth are the absence of experienced professionals to examine the ASD. Also, the time and efficiency required for caring and treating the patients that result in obstacles in the market.

AUTISM SPECTRUM DISORDER TREATMENT MARKET REPORT COVERAGE

CLICK HERE TO DOWNLOAD SAMPLE

Segmentation Analysis

The research report on the global Autism Spectrum Disorder Treatment Market has been segmented and sub-segmented based on type, and treatment. 

Autism Spectrum Disorder Treatment Market - By Type

• Autistic Disorder
• Asperger Syndrome
• Pervasive Developmental Disorder
• Childhood Disintegrative Disorder

By type, the Autistic disorder segment is dominating the autism spectrum disorder treatment market, in terms of revenue, in 2022. The segment growth owes to the increasing occurrence of autistic order and the rising need for efficient therapy for autism disorder treatment. 

In 2022, around 1 in 270 people are diagnosed with autism disorder, as per the World Health Organization (WHO). The factor helps om bosting the Autism spectrum disorder market globally.

The Asperger syndrome segment is projected to grow with the quickest CAGR pace of 0.85% due to escalating neurodevelopmental disorders that surge the insomnia cases and epilepsy, which hikes the growth of the segment globally. 

Autism Spectrum Disorder Treatment Market - By Treatment

• Behavioral Approaches
• Early Interventions
• Medication
• Dietary Approaches
• Others

The behavioral approaches segment records the largest dominating share in terms of revenue due to its coherence to understand and ease for practice. 

The early intervention segment is proposed to have the quickest CAGR of 2.0%% during the forecast period. The segment growth depends on improving the development of a child with different needs hold to permit families of children, boosts the market growth globally. 

Regional Analysis

Geographically, North America is said to dominate the autism spectrum disorder treatment market with the highest share in 2022. Factors owing to the market growth include a rising number of patients with autism and people having sound knowledge about the autism disorder. The United States is leading the autism spectrum disorder treatment market in the region. The ASD diagnosis rate has surged from 3.57% to 4.55% from 2014 to 2016, as per the Center for Disease Control and Prevention (CDC). In Canada, thousands of independents are affected by autism spectrum disorder. As per 2015 data, 1 in 66 Canadian children and ages of 5-17 are diagnosed with autism. In Canada, males are examined with autism more frequently than females. 

Europe is ranked second for the autism spectrum disorder (ASD) treatment market in terms of revenue. The growth in the region owes to increasing consciousness in people regarding various therapies for ASD management.

However, the autism spectrum disorder market in Asia-Pacific is estimated to grow with a considerable growth during the historical period. The region's growth owes to the rising occurrence of ASD among the China and Indian populations. Also, due to rising public and private organizations is augmenting treatment in patients with ASD. For example, Autism by the National Center for Autism India invented the autism movement in India by organizing the "Global Giving Program".  

Latin America is the second-highest region growing with stable growth in the ASD market. In Argentina, 30,000 people are diagnosed with ASD. 

The autism spectrum disorder treatment market in Middle East & African region is expected to have significant growth in the upcoming years. UAE, Africa, Israel contribute a major share towards the region's growth. 

Key Market Players

Curemark LLC, Actavis, Inc., Otsuka Holdings Co., Ltd., Janssen Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mylan Pharmaceuticals, Inc., Pediatric BioScience, Inc., Bristol-Myers Squibb, Merck & Co., Novartis AG, Pfizer Inc., and Par Sterile Products, LLC.

In 2018, .Hoffmann-La Roche Ltd received FDA approval for its new drug Balovaptan for treating ASD. The oral drug is used to enhance core social interaction and communication in patients with ASD. 

Bristol Mayers Squibb and Otsuka Holdings Co. Ltd combined to introduce ABILIFY drug for treating autistic disorder conditions. 

Recent Market Developments

• On July 30, 2022, Novartis partnered with Sangamo Therapeutics. The two companies develop therapies based on Zinc Finger technology targeting genes linked to autism spectrum disorder, neuro disorders, and intellectual disability. 
• On May 06, 2022, Curemark, LLC disclosed the Phase 3 clinical trials results, the Blum Study, presented at the International Study of Autism Research (INSAR).
• On December 04, 2022, Clarifi ASD was released by Quadrant Biosciences Inc. Company. Clarifi ASD is the epigenetic test for Autism spectrum disorder (ASD). The epigenetic test is to examine autism in children from 18 months to 6years of age.